Effect of venlafaxine on imipramine metabolism

被引:25
作者
Albers, LJ
Reist, C
Vu, RL
Fujimoto, K
Ozdemir, V
Helmeste, D
Poland, R
Tang, SW
机构
[1] Univ Calif Irvine, Coll Med, Dept Psychiat, Irvine, CA 92697 USA
[2] VA Healthcare Syst, Dept Mental Hlth, Long Beach, CA 90822 USA
[3] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[4] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[5] Ctr Addict & Mental Hlth, Neurogenet Sect, Toronto, ON, Canada
[6] Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA
关键词
antidepressant; tricyclic; desipramine; human cytochrome P450; pharmacokinetics; drug-drug interactions;
D O I
10.1016/S0165-1781(00)00213-4
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The present study was: designed to determine the effect of venlafaxine on imipramine metabolism in an attempt to elucidate the potential for cytochrome P450 drug-drug interactions with venlafaxine. We examined the metabolism of a single 100-mg dose of imipramine before and after treatment with venlafaxine, 50 mg three times a day. Eight male subjects were phenotyped for CYP2D6 activity. Two subjects were poor metabolizers of dextromethophan, and data from the remaining six subjects (mean age = 45.3 +/- 15) were analyzed. Venlafaxine increased imipramine C-max and elevated AUC by 40%. Desipramine clearance and volume of distribution were reduced by 20% and 25%, respectively. These findings are consistent with a statistically significant, but clinically modest impact of venlafaxine on CYP2D6-metabolized substrates. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:235 / 243
页数:9
相关论文
共 36 条
[1]   Paroxetine shifts imipramine metabolism [J].
Albers, LJ ;
Reist, C ;
Helmeste, D ;
Vu, R ;
Tang, SW .
PSYCHIATRY RESEARCH, 1996, 59 (03) :189-196
[2]  
Amchin J, 1998, PSYCHOPHARMACOL BULL, V34, P211
[3]  
Amchin J, 1998, PSYCHOPHARMACOL BULL, V34, P383
[4]  
Amchin J., 1997, Clinical Pharmacology and Therapeutics, V61, P179
[5]  
Amchin J, 1999, J CLIN PHARMACOL, V39, P252
[6]  
AMCHIN JD, 1996, ANN M AM PSYCH ASS N
[7]  
Ball S., 1996, Clinical Pharmacology and Therapeutics, V59, P170, DOI 10.1038/sj.clpt.1996.180
[8]   Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; Comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYPIA2 [J].
Ball, SE ;
Ahern, D ;
Scatina, J ;
Kao, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (06) :619-626
[9]   Clinical evaluation of venlafaxine [J].
Ballenger, JC .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (03) :S29-S35
[10]   QUANTIFICATION AND MECHANISM OF THE FLUOXETINE AND TRICYCLIC ANTIDEPRESSANT INTERACTION [J].
BERGSTROM, RF ;
PEYTON, AL ;
LEMBERGER, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) :239-248